Cancer Chemotherapy and Pharmacology

, Volume 70, Issue 6, pp 791–799 | Cite as

Phase I study of nelfinavir in liposarcoma

  • Janet Pan
  • Michelle Mott
  • Bixin Xi
  • Ernestine Hepner
  • Min Guan
  • Kristen Fousek
  • Rachel Magnusson
  • Raechelle Tinsley
  • Frances Valdes
  • Paul Frankel
  • Timothy Synold
  • Warren A. Chow
Original Article

Abstract

Purpose

HIV protease inhibitors are associated with HIV protease inhibitor–related lipodystrophy syndrome. We hypothesized that liposarcomas would be similarly susceptible to the apoptotic effects of an HIV protease inhibitor, nelfinavir.

Methods

We conducted a phase I trial of nelfinavir for liposarcomas. There was no limit to prior chemotherapy. The starting dose was 1,250 mg twice daily (Level 1). Doses were escalated in cohorts of three to a maximally evaluated dose of 4,250 mg (Level 5). One cycle was 28 days. Steady-state pharmacokinetics (PKs) for nelfinavir and its primary active metabolite, M8, were determined at Levels 4 (3,000 mg) and 5.

Results

Twenty subjects (13 males) were enrolled. Median (range) age was 64 years (37–81). One subject at Level 1 experienced reversible, grade 3 pancreatitis after 1 week and was replaced. No other dose-limiting toxicities were observed. Median (range) number of cycles was 3 (0.6–13.5). Overall best responses observed were 1 partial response, 1 minor response, 4 stable disease, and 13 progressive disease. Mean peak plasma levels and AUCs for nelfinavir were higher at Level 4 (7.3 mg/L; 60.9 mg/L × h) than 5 (6.3 mg/L; 37.7 mg/L × h). The mean ratio of M8:nelfinavir AUCs for both levels was ~1:3.

Conclusions

PKs demonstrate auto-induction of nelfinavir clearance at the doses studied, although the mechanism remains unclear. Peak plasma concentrations were within range where anticancer activity was demonstrated in vitro. M8 metabolite is present at ~1/3 the level of nelfinavir and may also contribute to the anticancer activity observed.

Keywords

Nelfinavir Phase I Liposarcoma Pharmacokinetics 

References

  1. 1.
    Fletcher CDM, Rydholm A, Singer S, Sudaram M, Coindre JM (2002) Soft tissue tumours: epidemiology, clinical features, histopathological typing and grading. In: Fletcher CDM, Unni KK, Mertens F (eds) Pathology & genetics: tumours of soft tissue and bone. IARC Press, Lyon, pp 9–19Google Scholar
  2. 2.
    Flexner C (1998) HIV-protease inhibitors. N Engl J Med 338:1281–1292PubMedCrossRefGoogle Scholar
  3. 3.
    Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus. Lancet 353:2093–2099PubMedCrossRefGoogle Scholar
  4. 4.
    Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD et al (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. JAMA 29(2):191–201CrossRefGoogle Scholar
  5. 5.
    Brinkman K, Smeitink JA, Romjin JA, Reiss P (1999) Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354:1112–1115PubMedCrossRefGoogle Scholar
  6. 6.
    Caron M, Auclair M, Vigourox C, Glorian M, Forest C, Capeau J (2001) The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50:1378–1388PubMedCrossRefGoogle Scholar
  7. 7.
    Nguyen AT, Gagnon AM, Angel JB, Sorisky A (2000) Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS 14:2467–2473PubMedCrossRefGoogle Scholar
  8. 8.
    Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C et al (2002) Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359:1026–1031PubMedCrossRefGoogle Scholar
  9. 9.
    Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331–340PubMedCrossRefGoogle Scholar
  10. 10.
    Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS (1997) Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99:838–845PubMedCrossRefGoogle Scholar
  11. 11.
    Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME et al (2004) Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 64:2212–2221PubMedCrossRefGoogle Scholar
  12. 12.
    Sakai J, Nohturfft A, Goldstein JL, Brown MS (1998) Cleavage of sterol regulatory element-binding proteins (SREBPs) at stie-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J Biol Chem 273:5785–5793PubMedCrossRefGoogle Scholar
  13. 13.
    Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R et al (2002) Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 110:489–500PubMedCrossRefGoogle Scholar
  14. 14.
    Brown MS, Ye J, Rawson RB, Goldstein JL (2000) Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100:391–398PubMedCrossRefGoogle Scholar
  15. 15.
    Guan M, Fousek K, Jiang C, Guo S, Synold T, Xi B et al (2011) Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin Cancer Res 17:1796–1806PubMedCrossRefGoogle Scholar
  16. 16.
    Chow WA, Guo S, Valdes-Albini F (2006) Nelfinavir induces liposarcoma apoptosis and cell-cycle arrest by upregulating sterol regulatory element binding protein-1. Anticancer Drugs 17:891–903PubMedCrossRefGoogle Scholar
  17. 17.
    Von Hoff D, Kuhn J, Clark GM (1985) Design and conduct of phase I trials. In: Buyse ME, Staquet MJ, Sylvester RJ (eds) Cancer clinical trials: methods and practice. Oxford University Press, OxfordGoogle Scholar
  18. 18.
    Therasse P, Arbuck S, Eisenhauser E, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  19. 19.
    Di Martino V, Ezenfis J, Benahmou Y, Bernard B, Opolon P, Bricaire F et al (1999) Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. AIDS 13:1421PubMedCrossRefGoogle Scholar
  20. 20.
    Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV et al (1998) Characterisation of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26:609–616PubMedGoogle Scholar
  21. 21.
    Merry C, Barry M, Ryan M, Gibbons S, Tijia J, Mulcahy F, Back D. A study of the pharmacokinetics of repetitive dosing with nelfinavir. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, 1999, Abstract 831Google Scholar
  22. 22.
    Burton ME, Shaw LM, Schentag JJ, Evans WE (2006) Applied pharmacokinetics & pharmacodynamics principles of therapeutic drug monitoring. Lippincott Williams & Wilkins, USAGoogle Scholar
  23. 23.
    Jones RL, Fisher C, Al-Muderis O, Judson IR (2005) Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 41:2853–2860PubMedCrossRefGoogle Scholar
  24. 24.
    Gupta AK, Lin G, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A (2007) The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 9:271–278PubMedCrossRefGoogle Scholar
  25. 25.
    Jiang Z, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ et al (2007) Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 67:4467–4472PubMedCrossRefGoogle Scholar
  26. 26.
    Yang Y, Ikezoe T, Takeuchi T, Adachi Y, Ohtsuki Y, Takeuchi S et al (2005) HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 96:425–433PubMedCrossRefGoogle Scholar
  27. 27.
    Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC (2007) HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 67:10920–10928PubMedCrossRefGoogle Scholar
  28. 28.
    Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, et al. (2007) Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 13, 5183–5194Google Scholar
  29. 29.
  30. 30.
    Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A et al (2008) A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 26:2699–2706PubMedCrossRefGoogle Scholar
  31. 31.
    De La Garza GO, Ismail AF, Anderson CM, Werner WW, Mihem MM, Hoffman HT et al (2011) Nelfinavir treatment of adenoid cystic carcinoma. A case report, Practical Radiation OncolGoogle Scholar
  32. 32.
    Chow WA, Jiang C, Guan M (2009) Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 10:61–71Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Janet Pan
    • 1
  • Michelle Mott
    • 3
  • Bixin Xi
    • 2
  • Ernestine Hepner
    • 3
  • Min Guan
    • 2
  • Kristen Fousek
    • 2
  • Rachel Magnusson
    • 1
  • Raechelle Tinsley
    • 4
  • Frances Valdes
    • 5
  • Paul Frankel
    • 6
  • Timothy Synold
    • 2
  • Warren A. Chow
    • 1
    • 2
  1. 1.Department of Medical OncologyCity of HopeDuarteUSA
  2. 2.Department of Molecular PharmacologyBeckman Research Institute of City of HopeDuarteUSA
  3. 3.Department of Hematology/HCTCity of HopeDuarteUSA
  4. 4.Clinical Trials OfficeCity of HopeDuarteUSA
  5. 5.Department of Medical OncologyUniversity of MiamiMiamiUSA
  6. 6.Department of Information SciencesCity of HopeDuarteUSA

Personalised recommendations